Suppr超能文献

相似文献

1
High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.
J Thromb Haemost. 2020 Sep;18(9):2329-2340. doi: 10.1111/jth.14972. Epub 2020 Aug 27.
2
Role of the coagulation system in the pathogenesis of sickle cell disease.
Blood Adv. 2019 Oct 22;3(20):3170-3180. doi: 10.1182/bloodadvances.2019000193.
4
The Plasma Kallikrein-Kininogen Pathway Is Critical in the Pathogenesis of Colitis in Mice.
Front Immunol. 2018 Feb 6;9:21. doi: 10.3389/fimmu.2018.00021. eCollection 2018.
7
Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.
Blood. 2015 Oct 8;126(15):1844-55. doi: 10.1182/blood-2015-01-625707. Epub 2015 Aug 18.
8
Biased agonism of protease-activated receptor-1 regulates thromboinflammation in murine sickle cell disease.
Blood Adv. 2024 Jun 25;8(12):3272-3283. doi: 10.1182/bloodadvances.2023011907.
9
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
J Thromb Haemost. 2016 Oct;14(10):1941-1952. doi: 10.1111/jth.13416. Epub 2016 Aug 31.
10
A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
J Thromb Haemost. 2017 Sep;15(9):1807-1817. doi: 10.1111/jth.13760. Epub 2017 Aug 2.

引用本文的文献

2
Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease.
Blood. 2023 Apr 13;141(15):1871-1883. doi: 10.1182/blood.2022017074.
3
Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo.
Blood Adv. 2023 Apr 11;7(7):1156-1167. doi: 10.1182/bloodadvances.2021006485.
4
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms.
Res Pract Thromb Haemost. 2022 Oct 13;6(7):e12815. doi: 10.1002/rth2.12815. eCollection 2022 Oct.
5
The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy.
Res Pract Thromb Haemost. 2021 May 3;5(4):e12504. doi: 10.1002/rth2.12504. eCollection 2021 May.

本文引用的文献

1
Receptor for Advanced Glycation End Products Antagonism Blunts Kidney Damage in Transgenic Townes Sickle Mice.
Front Physiol. 2019 Jul 23;10:880. doi: 10.3389/fphys.2019.00880. eCollection 2019.
2
Elimination of the fibrinogen integrin αβ-binding motif improves renal pathology in mice with sickle cell anemia.
Blood Adv. 2019 May 14;3(9):1519-1532. doi: 10.1182/bloodadvances.2019032342.
4
Hereditary angioedema: the plasma contact system out of control.
J Thromb Haemost. 2018 Sep;16(9):1674-1685. doi: 10.1111/jth.14209. Epub 2018 Jul 17.
5
Renal protection by atorvastatin in a murine model of sickle cell nephropathy.
Br J Haematol. 2018 Apr;181(1):111-121. doi: 10.1111/bjh.15157. Epub 2018 Mar 12.
6
Role of TLR4 signaling in the nephrotoxicity of heme and heme proteins.
Am J Physiol Renal Physiol. 2018 May 1;314(5):F906-F914. doi: 10.1152/ajprenal.00432.2017. Epub 2017 Oct 4.
7
Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.
J Am Soc Nephrol. 2017 Aug;28(8):2443-2458. doi: 10.1681/ASN.2016070711. Epub 2017 Mar 27.
8
Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):E5182-91. doi: 10.1073/pnas.1600311113. Epub 2016 Aug 8.
9
Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
J Thromb Haemost. 2016 Oct;14(10):1941-1952. doi: 10.1111/jth.13416. Epub 2016 Aug 31.
10
Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication.
Exp Biol Med (Maywood). 2016 Apr;241(7):679-88. doi: 10.1177/1535370216640385. Epub 2016 Mar 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验